Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and d

Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and d

A Story by Medicilon
"

Recently, Shanghai Medicilon Inc. (Medicilon) and EyeCure reached a strategic collaboration. The two parties will carry out comprehensive collaboration in the field of ophthalmic cell and gene therap

"

Recently, Shanghai Medicilon Inc. (Medicilon) and EyeCure reached a strategic collaboration.  The two parties will carry out comprehensive collaboration in the field of ophthalmic cell and gene therapy.

Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and development of ophthalmic cell and gene drugs.webp

Since its establishment in 2015, EyeCure has been deeply involved in the field of ophthalmic cell and gene therapy.  Its research and development focus on the development of human retinal pigment epithelial cells, corneal cells and mesenchymal stem cells, creating a new therapeutic field of using adult RPE cells to treat age-related macular degeneration and pigmentary degeneration.  Medicilon, as a one-stop preclinical biopharmaceutical comprehensive R&D service CRO, has also been deeply involved in the field of ophthalmic drugs for many years, and has established the "Medicilon Preclinical Ophthalmic Drug Research Platform" which can provide efficient, high-quality, and cost-effective drug discovery, pharmaceutical research, preclinical research services.

Medicilon Preclinical Ophthalmic Drug Development Platform
Help EyeCure to accelerate the development of new ophthalmic drugs 

Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and development of ophthalmic cell and gene drugs-1.webp

Complementary advantages in resources and a high degree of compatibility in vision allow Medicilon and EyeCure to achieve two-way development.  In this collaboration, relying on Medicilon's one-stop biopharmaceutical preclinical research and development service platform, Medicilon will provide EyeCure with services including but not limited to drug discoverypharmaceutical researchpreclinical research and comprehensive projects to assist in the development of a new class 1 ophthalmology drug.

© 2023 Medicilon


My Review

Would you like to review this Story?
Login | Register




Share This
Email
Facebook
Twitter
Request Read Request
Add to Library My Library
Subscribe Subscribe


Stats

39 Views
Added on July 18, 2023
Last Updated on July 18, 2023
Tags: drug discovery, pharmaceutical research, preclinical research, ophthalmology drug

Author

Medicilon
Medicilon

Cambridge, MA



About
Medicilon is an integrated contract research organization (CRO), providing comprehensive one-stop new drug R&D services for pharmaceutical enterprises and scientific research institutions around the w.. more..

Writing